Internal and Emergency Medicine

, Volume 8, Issue 6, pp 521–527 | Cite as

Evaluation of community-acquired sepsis by PIRO system in the emergency department

  • Yun-Xia Chen
  • Chun-Sheng LiEmail author


The predisposition, infection/insult, response, and organ dysfunction (PIRO) staging system for septic patients allows grouping of heterogeneous patients into homogeneous subgroups. The purposes of this single-center, prospective, observational cohort study were to create a PIRO system for patients with community-acquired sepsis (CAS) presenting to the emergency department (ED) and assess its prognostic and stratification capabilities. Septic patients were enrolled and allocated to derivation (n = 831) or validation (n = 860) cohorts according to their enrollment dates. The derivation cohort was used to identify independent predictors of mortality and create a PIRO system by binary logistic regression analysis, and the prognostic performance of PIRO was investigated in the validation cohort by receiver operator characteristic (ROC) curve. Ten independent predictors of 28-day mortality were identified. The PIRO system combined the components of predisposition (age, chronic obstructive pulmonary disease, hypoalbuminemia), infection (central nervous system infection), response (temperature, procalcitonin), and organ dysfunction (brain natriuretic peptide, troponin I, mean arterial pressure, Glasgow coma scale score). The area under the ROC of PIRO was 0.833 for the derivation cohort and 0.813 for the validation cohort. There was a stepwise increase in 28-day mortality with increasing PIRO score and the differences between the low- (PIRO 0–10), intermediate- (11–20), and high- (>20) risk groups were very significant in both cohorts (p < 0.01). The present study demonstrates that this PIRO system is valuable for prognosis and risk stratification in patients with CAS in the ED.


PIRO Prognosis Risk stratification Sepsis 



We thank all physicians, nursing staff, and patients who participated in this study.

Conflict of interest



  1. 1.
    Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shofer FS, Goyal M (2010) Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38(4):1045–1053PubMedCrossRefGoogle Scholar
  2. 2.
    Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, Peters C, Ahsan M, Chateau D (2009) Cooperative antimicrobial therapy of septic shock database research group: initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136(5):1237–1248PubMedCrossRefGoogle Scholar
  3. 3.
    Lee CC, Lee CH, Chuang MC, Hong MY, Hsu HC, Ko WC (2012) Impact of inappropriate empirical antibiotic therapy on outcome of bacteremic adults visiting the ED. Am J Emerg Med 30(8):1447–1456PubMedCrossRefGoogle Scholar
  4. 4.
    Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 29(4):530–538PubMedCrossRefGoogle Scholar
  5. 5.
    Moreno RP, Metnitz B, Adler L, Hoechtl A, Bauer P, Metnitz PG (2008) Sepsis mortality prediction based on predisposition, infection and response. Intensive Care Med 34(3):496–504PubMedCrossRefGoogle Scholar
  6. 6.
    Rubulotta F, Marshall JC, Ramsay G, Nelson D, Levy M, Williams M (2009) Predisposition, insult/infection, response, and organ dysfunction: a new model for staging severe sepsis. Crit Care Med 37(4):1329–1335PubMedCrossRefGoogle Scholar
  7. 7.
    Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR (2003) Recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) study group: effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31(3):834–840PubMedCrossRefGoogle Scholar
  8. 8.
    Beale R, Reinhart K, Brunkhorst FM, Dobb G, Levy M, Martin G, Martin C, Ramsey G, Silva E, Vallet B, Vincent JL, Janes JM, Sarwat S, Williams MD (2009) PROGRESS advisory board: promoting global research excellence in severe sepsis (PROGRESS): lessons from an international sepsis registry. Infection 37(3):222–232PubMedCrossRefGoogle Scholar
  9. 9.
    Howell MD, Talmor D, Schuetz P, Hunziker S, Jones AE, Shapiro NI (2011) Proof of principle: the predisposition, infection, response, organ failure sepsis staging system. Crit Care Med 39(2):322–327PubMedCrossRefGoogle Scholar
  10. 10.
    Granja C, Póvoa P, Lobo C, Teixeira-Pinto A, Carneiro A, Costa-Pereira A (2013) The predisposition, infection, response and organ failure (Piro) sepsis classification system: results of hospital mortality using a novel concept and methodological approach. PLoS One 8(1):e53885PubMedCrossRefGoogle Scholar
  11. 11.
    de Groot B, de Deckere ER, Flameling R, Sandel MH, Vis A (2012) Performance of illness severity scores to guide disposition of emergency department patients with severe sepsis or septic shock. Eur J Emerg Med 19(5):316–322PubMedCrossRefGoogle Scholar
  12. 12.
    Zahar JR, Timsit JF, Garrouste-Orgeas M, Français A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaouchiche B, Azoulay E, Adrie C (2011) Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med 39(8):1886–1895PubMedCrossRefGoogle Scholar
  13. 13.
    Schuetz P, Albrich W, Mueller B (2011) Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 9:107PubMedCrossRefGoogle Scholar
  14. 14.
    Dahaba AA, Hagara B, Fall A, Rehak PH, List WF, Metzler H (2006) Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 97(4):503–508PubMedCrossRefGoogle Scholar
  15. 15.
    Castelli GP, Pognani C, Cita M, Stuani A, Sgarbi L, Paladini R (2006) Procalcitonin, C-reactive protein, white blood cells and SOFA score in ICU: diagnosis and monitoring of sepsis. Minerva Anestesiol 72(1–2):69–80PubMedGoogle Scholar
  16. 16.
    Lee CC, Chen SY, Tsai CL, Wu SC, Chiang WC, Wang JL, Sun HY, Chen SC, Chen WJ, Hsueh PR (2008) Prognostic value of mortality in emergency department sepsis score, procalcitonin, and C-reactive protein in patients with sepsis at the emergency department. Shock 29(3):322–327PubMedGoogle Scholar
  17. 17.
    Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39(2):206–217PubMedCrossRefGoogle Scholar
  18. 18.
    Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B (2009) Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302(10):1059–1066PubMedCrossRefGoogle Scholar
  19. 19.
    Nguyen HB, Van Ginkel C, Batech M, Banta J, Corbett SW (2012) Comparison of predisposition, insult/infection, response, and organ dysfunction, acute physiology and chronic health evaluation II, and mortality in emergency department sepsis in patients meeting criteria for early goal-directed therapy and the severe sepsis resuscitation bundle. J Crit Care 27(4):362–369PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2013

Authors and Affiliations

  1. 1.Department of Emergency MedicineBeijing Chao-Yang Hospital, Affiliated To Capital Medical UniversityBeijingChina

Personalised recommendations